Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGR-hTNF + pegylated liposomal doxorubicin
- Development stage
- Discontinued
- Lead developer
- AGC Biologics
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NGR-hTNF + pegylated liposomal doxorubicin is a combination drug regimen consisting of a tumor vessel-targeting fusion protein (NGR-hTNF) and a liposomal formulation of the chemotherapy agent doxorubicin. NGR-hTNF is a recombinant protein in which the human tumor necrosis factor-alpha (hTNF-α) is fused with an NGR (asparagine-glycine-arginine) peptide, directing it specifically to CD13 isoforms overexpressed on tumor endothelium. This targeting increases local cytokine concentrations within tumor vasculature, impairing pro-survival signaling and enhancing tumor vessel permeability, thus promoting intratumoral delivery of therapies[1][3]. Pegylated liposomal doxorubicin (PLD, Caelyx) is doxorubicin encapsulated in pegylated (polyethylene glycol-coated) liposomes, prolonging its circulation time and favoring deposition into tumors by exploiting leaky tumor vasculature. Its antineoplastic activity comes from inhibiting topoisomerase II, leading to DNA strand breaks and cell death[2][4]. The combination is developed to enhance chemotherapy penetration and efficacy by combining vessel-targeted cytokine therapy with cytotoxic chemotherapy.
- Brand names
- Caelyx
- Other names
- NGR-hTNF + PLDNGR-hTNF + Caelyx
02
Targets
DNATOP2A (DNA topoisomerase II)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)ANPEP (Aminopeptidase N)
Beyond the preview
Go deeper on NGR-hTNF + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGR-hTNF + pegylated liposomal doxorubicin.